Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Accured Expenses (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Change in Accured Expenses data on record, last reported at -$550000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 12.28% year-over-year to -$550000.0; the TTM value through Sep 2025 reached $297000.0, up 114.1%, while the annual FY2024 figure was $350000.0, 164.81% up from the prior year.
  • Change in Accured Expenses reached -$550000.0 in Q3 2025 per RANI's latest filing, down from $388000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.4 million in Q2 2023 and bottomed at -$2.2 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $61157.9, with a median of $323000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1452.94% in 2021, then crashed 693.67% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$1.6 million in 2021, then decreased by 11.08% to -$1.8 million in 2022, then dropped by 21.46% to -$2.2 million in 2023, then soared by 113.33% to $289000.0 in 2024, then tumbled by 290.31% to -$550000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$550000.0 in Q3 2025, $388000.0 in Q2 2025, and $170000.0 in Q1 2025.